Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation

wockhardt limited
SMART_READER_LITE
LIVE PREVIEW

Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation

Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q4FY15 & FY14-15 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or


slide-1
SLIDE 1

Wockhardt Limited

Investor Presentation By

  • Dr. Murtaza Khorakiwala

Managing Director Q4FY15 & FY14-15

slide-2
SLIDE 2

Safe Harbor Statement

  • Except for historical information contained herein, statements in this communication, which include

words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other

  • risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to

reflect events or circumstances after the date thereof.

Investor Presentation May 2015 2

slide-3
SLIDE 3

Introduction to Wockhardt

Key Business Dynamics

slide-4
SLIDE 4

ROW operations Wockhardt Direct

  • perations

USA UK, Ireland, France, Switz. India

Mexico

Wockhardt Today

Investor Presentation May 2015 4

Direct Operations in India, USA and Europe

8600 Associates employed in 21 countries

slide-5
SLIDE 5

UK Ireland

Wockhardt Today

Investor Presentation May 2015 5

12

Manufacturing Locations globally

Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Baddi Chicago

Formulations APIs 9 sites in India

slide-6
SLIDE 6

Wockhardt Today

Investor Presentation May 2015 6

3 R&D Centers

worldwide

USA / UK & India

slide-7
SLIDE 7

Key Business Update

slide-8
SLIDE 8

Key Business Update

Investor Presentation May 2015 8

  • UK MHRA lifted Statement of Non Compliance from L1 Facility and have also restored

EU GMP certification of Kadaiya facility.

  • MGP Facility:- 483 response was found satisfactory from US FDA.
  • US FDA conducted inspection in L1 & Waluj facilities & observed on going improvement

in company's efforts towards compliance.

  • Obtained QIDP status from US FDA for 2 of its drugs WCK 771 & WCK 2349 for New Drug

Discovery program in Anti-infective research in FY15. Also obtained QIDP status for its third NCE product WCK 4873 during this month. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.

  • Filed for 267 patents during the Year taking the cumulative filings to 2268 and has been

granted 82 patents during the Year taking the cumulative patents granted to 341.

Regulatory Update Research Update

slide-9
SLIDE 9

Q4FY15 Results

slide-10
SLIDE 10

Sales – Growth of 4% over Q4FY14

Investor Presentation May 2015 10

Rs.crore Growth of 4% in Q4FY15 over Q4FY14

slide-11
SLIDE 11

EBITDA – Growth of 11% over Q4FY14

Investor Presentation May 2015 11

Rs.crore Growth of 11% in Q4FY15 over Q4FY14

slide-12
SLIDE 12

PAT – Decline of 55% over Q4FY14

Investor Presentation May 2015 12

Rs.crore De-growth of 55% in Q4FY15 over Q4FY14

slide-13
SLIDE 13

FY 14-15 Results

slide-14
SLIDE 14

Sales – Decline of 7% over FY 13-14

Investor Presentation May 2015 14

Rs.crore Decline of 7% in FY 14-15 over FY 13-14

slide-15
SLIDE 15

EBITDA – Declines by 16% over FY 13-14

Investor Presentation May 2015 15

Rs.crore Declines by 16% in FY 14-15 over FY 13-14

slide-16
SLIDE 16

PAT – Declines by 52% over FY 13-14

Investor Presentation May 2015 16

Rs.crore Declines by 52% in FY 14-15 over FY 13-14

slide-17
SLIDE 17

Research – 11.5% of Sales in FY14-15

Investor Presentation May 2015 17

slide-18
SLIDE 18

US Business

Investor Presentation May 2015 18

  • Declines by 21% (22% in $ terms)
  • ver Q4FY14.
  • Declines by 49% (51% in $ terms)
  • ver FY 13-14.
  • During the year 14 ANDA’s filed &

cumulative ANDA’s pending for approval is 69.

2,150 1,087

  • 500

1,000 1,500 2,000 2,500 FY 13-14 FY 14-15

USA

Rs.cr.

$364 $179

slide-19
SLIDE 19

EU Operations

UK Operations

  • 8 New Approvals received in FY 14-15.
  • 11 New Fillings done in FY 14-15 , 1 in Q4FY15.
  • UK operation Grows by 36% (grows by 34% £ terms) in
  • Q4FY15. Grows by 46% (35% in £ terms) in FY 14-15.
  • Among top 5 generic company.

Investor Presentation May 2015 19

Ireland Operations

  • Ireland Declines by 11% (6% in € terms) in Q4FY15.

Decline by 10% (11% in € terms) in FY 14-15.

964 1,405

100 300 500 700 900 1,100 1,300 1,500 FY 13-14 FY 14-15

UK

Rs.cr. £ 104 £ 141 176 158

  • 50

100 150 200 250 FY 13-14 FY 14-15

Ireland

Rs.cr. € 22 € 20

slide-20
SLIDE 20

India & Emerging Markets

  • Total Emerging Markets (Including India)

Grows by 26% for Q4FY15. Grows by 19% for FY 14-15.

  • India Business Grows by 46% for Q4FY15

and Grows by 24% during FY 14-15.

  • 2 new products in Q4FY15 and 42 new

products launched in FY 14-15 in India.

  • Emerging Market operations declined by

25% in Q4FY15 and grew by 3% during FY 14-15.

Investor Presentation May 2015 20

998 India 1235 India

302 Em 312 Em

200 400 600 800 1,000 1,200 1,400 1,600 1,800 FY 13-14 FY 14-15

India & Emerging Markets (Em)

Rs.cr.

slide-21
SLIDE 21

Investor Presentation May 2015 21

For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com